Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Trial Profile

Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Blood coagulation disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Scarlet2
  • Sponsors Asahi Kasei Pharma America Corp
  • Most Recent Events

    • 14 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 1 Jul 2019.
    • 09 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top